# A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)

> **NCT01957202** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 71 (actual)

## Conditions studied

- Rhinitis, Allergic, Perennial and Seasonal

## Interventions

- **DRUG:** FF/levocabastine
- **DRUG:** FF
- **DRUG:** levocabastine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01957202
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2017-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01957202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01957202, "A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01957202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*